Cltrinin

Research use only, not for human use.

Citrinin (NSC 186) is a mycotoxin that causes food contamination and has different toxic effects. Citrinin is an effective oral anticancer agent. Citrinin has various regulatory effects on mouse immune system, including regulating the number of immune cells, inducing apoptosis and autophagy of immune cells, altering toll-like receptor expression and cytokine production. Citrinin can induce oxidative stress and lead to early apoptosis of oocytes. Low doses of Citrinin have neuroprotective effects against glutamate-induced excitotoxicity in rat cortical neurons. In addition, Citrinin also has antibacterial activity.

Citrinin is a mycotoxin that causes contamination in the food and is associated with different toxic effects. Citrinin also possesses a broad spectrum of bioactivities, including antifungal, antibacterial, and potential anticancer and neuroprotective effects in vitro.

Apoptosis Analysis Cell Line:Splenocytes and MLN cells from a SPF mouse ages 7 seven weeks old Concentration:1, 5 and 10 μg/mL Incubation Time:6 h Result:Significantly increased the number of late apoptotic cells, but not in early apoptotic cells.Western Blot Analysis Cell Line:Splenocytes Concentration:1, 5 and 10 μg/mL Incubation Time:6 h Result:Decreased the level of Bcl-2, and the expression of Bax was not affected.

Animal Model:Female BALB/c mice aged seven weeks oldDosage:1, 5, or 10 mg/kg Administration:Oral gavage (i.g.); 14 days Result:Significantly reduced the populations of F4/80+ cells and CD19+ cells in spleen and MLN. Increased the populations of CD4+, CD8+ and CD4+CD25+Foxp3+ cells in MLN. Increased the populations of CD8+ cells and decreased the populations of CD19+ cells in intra-epithelial, lamina propria and Peyer’s patches lymphocytes. Reduced IgM antibody production in serum. Increased the ratios of Bax/Bcl-2 in the spleen. Up-regulated the expression of Atg5, Beclin-1 and TLR 2 in the spleen.Animal Model:DMBA treated swiss albino female mice aged 6-7 weeks old (25-30 g) Dosage:2 mg/kg Administration:Oral administration (p.o.); 3 weeks Result:Reduced the weight of both breasts, and reduced cell proliferation in the breast. Did not cause necrosis in the cells, the characteristics of the carcinoma such as intraductal calcification, injured tissue, fibrosed with ductal hyperplasia, and histopathological characteristics indicative of preneoplasia still remained. Decreased genotoxic damage, damage index and damage frequency in breast and non-tumor cells induced by DMBA . Did not increase micronuclei or chromosomal bridge formation in hepatocytes of the animals.

———

Others

Other Targets

Others

———

———

518-75-2

250.25

C13H14O5

>98% (HPLC)

DMSO : 50 mg/mL (199.80 mM; ultraphonic; )

———

——

(-20℃)

With Ice Pack

≥ 2 years